posted on 2021-04-28, 09:58authored byFrancesco Massari, Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Giada Grilli, Alba Greco, Rodolfo Montironi, Andrea Ardizzoni
Supplementary
Figure 1. Funnel Plot of the Overall Survival (OS) in poor-risk patients,
according to IMDC criteria (immune checkpoint inhibitors plus tyrosine kinase
inhibitors versus sunitinib monotherapy).
Supplementary
Figure 2. Funnel Plot of the Overall Survival (OS) in intermediate-risk
patients, according to IMDC criteria (immune checkpoint inhibitors plus
tyrosine kinase inhibitors versus sunitinib monotherapy).
Supplementary Figure 3. Funnel Plot of the Overall Survival (OS) in favorable-risk patients,
according to IMDC criteria (immune checkpoint inhibitors plus tyrosine kinase
inhibitors versus sunitinib monotherapy).